Shearman & Sterling advised Credit Suisse and Kempen & Co as joint book-running managers on the initial public offering of European Biotech Acquisition Corp., a special-purpose acquisition company, of 12 million units at an offering price of $10 per unit, each unit consisting of one Class A ordinary share and one-third of one redeemable warrant.

European Biotech Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses in the life sciences industry in Europe.

The Team